EU Assessing Roche’s RoActemra For Hospitalized COVID-19 Patients
An EMA Opinion Is Expected In October
Executive Summary
Three authorized products currently used for arthritis and other conditions have now been filed for approval in Europe for treating people with severe COVID-19.
You may also be interested in...
Coronavirus Notebook: New Deal To Boost Local Vaccine Manufacturing, EU Warns Of RoActemra Shortages
MSF tells G20 leaders to “put your money where your mouth is” on vaccine sharing, the UK is considering whether to vaccinate all 12-15-year olds, and the UK & Australia are to swap excess vaccines.
Coronavirus Notebook: WHO Backs Actemra & Kevzara In COVID-19, German Body Says Remdesivir Has ‘Considerable Added Benefit’
The UK REACT-1 study has shown a threefold reduction in COVID-19 infections in double-vaccinated adults.
Coronavirus Update: Once Written Off, Roche's Actemra Finally Gets EUA In COVID-19
Actemra finally gains an emergency use authorization, Lilly's antibodies withdrawn again amid Delta variant concerns, plus Latin America’s belief in an anti-parasite drug in COVID-19 could soon be punctured.